Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics Inc. (NASDAQ: ESPR) is a pharmaceutical company developing and commercializing oral cholesterol-lowering medications for patients with cardiovascular disease risk. The company's news flow reflects its position as a commercial-stage biotech navigating product launches, partnership expansions, and ongoing clinical evidence generation in the cardiovascular therapeutics market.
News from Esperion typically covers developments across several key areas. Regulatory and partnership milestones feature prominently as the company works with international partners to secure approvals and launch its products in new markets. These announcements track the global expansion of NEXLETOL and NEXLIZET beyond the United States through licensing relationships with regional pharmaceutical companies.
Clinical data and medical society presentations represent another significant news category. Esperion regularly presents analyses from the CLEAR Outcomes cardiovascular trial at major cardiology conferences, generating coverage when new data subsets demonstrate product benefits in specific patient populations or when medical guidelines incorporate bempedoic acid recommendations.
Financial updates including quarterly earnings reports and capital markets activities provide insight into the company's commercial progress and cash position. As a small-cap pharmaceutical company balancing commercial investment against revenue generation, these disclosures help investors track the trajectory toward sustainable profitability.
Pipeline developments appear periodically as Esperion advances preclinical candidates and evaluates new therapeutic applications for its scientific platform beyond cholesterol management. Bookmark this page to follow Esperion's progress across commercial execution, clinical evidence generation, and research advancement.
Esperion (NASDAQ: ESPR) announced that bempedoic acid (NEXLETOL) is now recommended by the American College of Cardiology (ACC) as a vital non-statin therapy for LDL-cholesterol lowering in managing atherosclerotic cardiovascular disease (ASCVD). This update highlights the need for alternative options for patients who cannot achieve LDL-C goals with statins alone. Based on Phase III trial evidence, bempedoic acid has shown a 24.5% reduction in LDL-C levels. The ACC endorsement, along with other recommendations, supports the importance of non-statin therapies in clinical practice.
Esperion (NASDAQ: ESPR) granted 66,000 restricted stock units (RSUs) to 13 new employees on August 2, 2022, through its 2017 Inducement Equity Incentive Plan. This plan targets individuals who were not previous employees or directors, providing inducements for joining Esperion. The RSUs will vest 25% after one year and the remaining 75% in twelve equal quarterly installments, contingent upon continued employment. Esperion specializes in developing oral LDL-cholesterol lowering medications tailored for patients unmet by existing options.
Esperion reported significant progress in its CLEAR Outcomes Trial, achieving 100% of targeted MACE-4 events, with topline results expected in Q1 2023. In Q2 2022, U.S. product revenue for NEXLETOL and NEXLIZET increased by 28% year-over-year to $13.6 million, while total revenue stood at $18.8 million, reflecting a 54% decline from Q2 2021 due to a one-time payment last year. R&D expenses rose to $32.4 million, driven by trial costs, while SG&A expenses fell 36% to $29.6 million. The company reported a net loss of $66.3 million, improving loss per share to $1.05.
Esperion (NASDAQ: ESPR) announced the formation of its Scientific Advisory Board (SAB) on July 25, 2022. The board features esteemed experts in atherosclerosis and cardiovascular diseases, who will guide the company's research and development strategy. CEO Sheldon Koenig emphasized the importance of the SAB's role, especially as the CLEAR Outcomes trial results are imminent. Notable co-chairs include Peter Libby and Joanne Foody. The company aims to optimize its marketed products and pipeline assets, including an oral PCSK9 inhibitor.
Esperion (NASDAQ: ESPR) will report its second quarter 2022 financial results on August 2, 2022, before U.S. markets open. A conference call with management will commence at 8:00 a.m. ET to discuss the results and business updates. Esperion focuses on developing and commercializing innovative cholesterol-lowering therapies, including NEXLETOL® and NEXLIZET®. The live audio webcast of the call will be available on the company's investor website, with a replay accessible shortly after the call, archived for 90 days.
Esperion announced a significant real-world analysis involving over 400,000 high-risk patients for atherosclerotic cardiovascular disease (ASCVD), presented at the National Lipid Association Scientific Sessions. The study revealed that 46.9% of patients were not on any statin, with only 6.6% on under-dosed statins, highlighting a gap in guideline adherence for LDL-cholesterol therapies. Additionally, the use of non-statin lipid-lowering therapies was low at 8.1%. The findings emphasize the urgent need for increased education on appropriate lipid management treatments.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will present at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 9:00 AM (ET). The presentation will include a webcast available on the company's website, with a replay accessible two hours after the event for 90 days. Esperion is focused on developing oral, once-daily non-statin medications aimed at lowering LDL-cholesterol, catering especially to patients with unmet needs. More details can be found on their website.
Esperion (NASDAQ: ESPR) appointed J. Martin Carroll as Chairperson of its Board of Directors, effective immediately. Mr. Carroll's extensive experience, including leadership roles at Boehringer Ingelheim and Merck, positions him to provide strategic guidance as the company prepares for the upcoming CLEAR Outcomes trial results in early 2023. This leadership change aims to strengthen Esperion's efforts in commercializing its innovative cholesterol-lowering therapies.
Esperion (NASDAQ: ESPR) announced acceptance of five abstracts for presentation at the National Lipid Association Scientific Sessions 2022, highlighting research on bempedoic acid for patients with atherosclerotic cardiovascular disease and various metabolic conditions. CEO Sheldon Koenig emphasized the need for effective cholesterol management post-pandemic. The studies cover efficacy and safety details of bempedoic acid, particularly in patients with renal impairment and metabolic syndrome. The company aims to address significant public health gaps in cardiovascular care.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022. The event will feature a presentation and one-on-one meetings, starting at 7:00 am Eastern Standard Time. A live audio webcast will be accessible on the company’s website, with a replay available after the event. Esperion specializes in innovative cholesterol-lowering therapies, focusing on oral, once-daily non-statin medications for patients with high LDL-cholesterol levels.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
